(S)-N-(1-fluoro-3-phenylpropan-2-yl)-N-methylprop-2-yn-1-amine | 1146971-53-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-N-(1-fluoro-3-phenylpropan-2-yl)-N-methylprop-2-yn-1-amine
• 英文别名: (S)-N,N-methylpropargyl-1-fluoro-3-phenylpropan-2-amine；((S)-1-fluoromethyl-2-phenylethyl)-methyl-prop-2-ynylamine；(2S)-1-fluoro-N-methyl-3-phenyl-N-prop-2-ynylpropan-2-amine
• CAS: 1146971-53-0
• 化学式: C₁₃H₁₆FN
• 分子量: 205.275
• InChiKey: FPPVPPCQNSSPGJ-ZDUSSCGKSA-N

物化性质

• 沸点：
  291.2±35.0 °C(predicted)
• 密度：
  1.018±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (S)-2-(N,N-methylpropargylamino)-3-phenylpropan-1-ol 在 二乙胺基三氟化硫 作用下， 以 二氯甲烷 为溶剂， 反应 0.33h， 以21%的产率得到(S)-N-(1-fluoro-3-phenylpropan-2-yl)-N-methylprop-2-yn-1-amine
  参考文献：
  名称：

  Synthesis of Three Novel Fluorine-18 Labeled Analogues of l-Deprenyl for Positron Emission Tomography (PET) studies of Monoamine Oxidase B (MAO-B)

  摘要：

  The aim in this project was to synthesize and to study fluorine-18 labeled analogues of L-deprenyl which bind selectively to the enzyme monoamine oxidase B (MAO-B). Three fluorinated L-deprenyl analogues have been generated in multistep organic syntheses. The most promising fluorine-18 compound N-[(2S)-1-[F-18]fluoro-3-phenylpropan-2-yl]-N-methylprop-2-yn-1-amine (4c) was synthesized by a one-step fluorine-18 nucleophilic substitution reaction. Autoradiography on human brain tissue sections demonstrated specific binding for compound 4c to brain regions known to have a high content of MAO-B. In addition, the corresponding nonradioactive fluorine-19 compound (13) inhibited recombinant human MAO-B with an IC50 of 170.5 +/- 29 n/v1 but did not inhibit recombinant human MAO-A (IC50 > 2000 nM), demonstrating its specificity. Biodistribution of 4c in mice showed high initial brain uptake leveling at 5.4 +/- 0.04%ID/g after 2 min post injection. In conclusion, compound 4c is a specific inhibitor of MAO-B with high initial brain uptake in mice and is, therefore, a candidate for further investigation in PET.

  DOI：

  10.1021/jm200710b

文献信息

• Nucleophilic Fluorination and Radiofluorination via Aziridinium Intermediates: N-Substituent Influence, Unexpected Regioselectivity, and Differences between Fluorine-19 and Fluorine-18
  作者：Marie Médoc、Franck Sobrio

  DOI：10.1021/acs.joc.5b01714

  日期：2015.10.16

  reaction was heated to 90 °C, considerable changes appeared during radiofluorination. In the latter case, the radiochemical yields increased, and degradation of the 2-fluoro-propan-1-amine isomer (b) occurred, leading to a regiospecific reaction in the radiolabeling of [18F]-fluorodeprenyl. This method involving nucleophilic radiofluorination at RT was successfully applied to the radiolabeling of [18F]-2-fluoroethylamines

  开发了一种N，N-二取代-β-氨基醇通过邻氨基苯甲酸酯辅助机理进行有效的脱氟化氢和放射性氟化的方法。对N-取代基对叠氮基中间体的开环的影响的研究表明，从N，N-二取代-苯丙氨醇获得的氟化产物的异构体比率和产率上存在差异。这种影响对于18F-放射性氟化，在室温（RT）下产率从0到71％不等。虽然将反应加热到90°C时在氟19化学中未观察到明显影响，但在放射性氟化过程中出现了相当大的变化。在后一种情况下，放射化学收率增加，并且发生了2-氟-丙-1-胺异构体（b）的降解，从而在[ 18 F]-氟代异戊二烯的放射性标记中引起了区域特异性反应。这种涉及在室温下进行亲核放射性氟化的方法已成功地应用于[ 18 F] -2-氟乙胺的放射性标记，其中还观察到了N取代基的影响。
• Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP2450332A1

  公开（公告）日：2012-05-09

  This invention relates to novel compounds suitable as precursors for the preparation of certain 18F labelled positron emission tomography (PET) tracers. Furthermore, the invention relates to the preparation of such precursor molecules and to the preparation of PET tracers by 18F labelling of such precursors.

  本发明涉及适用作为某些18F标记正电子发射断层扫描（PET）示踪剂制备的前体的新化合物。此外，该发明涉及这种前体分子的制备以及通过对这种前体进行18F标记制备PET示踪剂。
• COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS
  申请人：Lehmann Lutz

  公开号：US20100233086A1

  公开（公告）日：2010-09-16

  This invention relates to novel compounds suitable for labelling or already labelled by 18 F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

  本发明涉及适用于标记或已经通过18F标记的新型化合物，制备这种化合物的方法，包含这种化合物的组合物，包含这种化合物或组合物的试剂盒以及这种化合物，组合物或试剂盒用于正电子发射断层摄影（PET）的诊断成像的用途。
• Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
  申请人：Bayer Schering Pharma AG

  公开号：EP2053033A1

  公开（公告）日：2009-04-29

  This invention relates to novel compounds suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

  本发明涉及适合标记或已经标记 18F 的新型化合物、制备此类化合物的方法、包含此类化合物的组合物、包含此类化合物或组合物的试剂盒以及此类化合物、组合物或试剂盒在正电子发射断层扫描（PET）诊断成像中的用途。
• Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP2374779A1

  公开（公告）日：2011-10-12

  This invention relates to novel compounds suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

  本发明涉及适合标记或已经标记 18F 的新型化合物、制备此类化合物的方法、包含此类化合物的组合物、包含此类化合物或组合物的试剂盒以及此类化合物、组合物或试剂盒在正电子发射断层扫描（PET）诊断成像中的用途。